Investment area
Seed Investments
Region
Europe
Date of investment
March 2021
Adcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug conjugates (ADCs) for treatment of cancers.
Contact
Jeroen Bakker
Partner
Department: Seed Investments
Jeroen Bakker joined Seed Investments in 2018.
Jeroen currently holds several board roles and led the investment in Adcendo and Rappta Therapeutics. Prior to joining Novo, Jeroen worked at M Ventures, the corporate venture capital arm of Merck, where he focused on Seed and Series A investments across Europe, United States Israel. He was instrumental in the Artsavit Ltd investment and served on multiple boards. Jeroen held a variety of operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego.
Jeroen holds a PhD in Immunology from the University of Amsterdam, an MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and an BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.
